Concepedia

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Mohamed I. A. Othman, Aileen L. Pangan, Heidi S. Camp

The Lancet · 2018 · 397 citations · 20 references

DOI

Concepts

References

20

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

D. Aletaha, Tuhina Neogi, Alan J. Silman et al. · Annals of the Rheumatic Diseases · 2010 · 4.9K citations · Full text

, , +13

American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

David T. Felson, Jennifer J. Anderson, Maarten Boers et al. · Arthritis & Rheumatism · 1995 · 2.8K citations

, , +16

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

George A. Wells, J-C Becker, J. Teng et al. · Annals of the Rheumatic Diseases · 2008 · 892 citations · Full text

, , +17

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman et al. · The Lancet · 2013 · 720 citations

, , +12

Baricitinib in Patients with Refractory Rheumatoid Arthritis

Mark C. Genovese, Joel Kremer, Omid Zamani et al. · New England Journal of Medicine · 2016 · 621 citations · Full text

, , +16